Genentech’s Tecentriq® plus chemotherapy helps reduce risk of ABC
Category: #health  By Mateen Dalal  Date: 2019-08-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Genentech’s Tecentriq® plus chemotherapy helps reduce risk of ABC

Data will be demonstrated at an upcoming medical meeting and shared with health authorities globally, including the U.S. FDA (Food and Drug Administration).

Genentech, a subsidiary of the Roche Group, recently announced that the Phase III IMvigor130 study has reached its investigator-assessed progression-free survival (PFS). According to sources, the combination of Tecentriq® (atezolizumab) plus chemotherapy (platinum-based) showed a drastic reduction in the risk of worsening disease or death in people with previously untreated metastatic urothelial carcinoma (mUC) when compared with chemotherapy only.

Speaking on the move, Sandra Horning, M.D., Chief Medical Officer & Head of Global Product Development, Roche Group, said that IMvigor130 is the first optimistic Phase III study of a cancer immunotherapy combination in formerly untreated Advanced Bladder Cancer (ABC), a violent disease with huge unmet need.

She said that these results back the company’s broad clinical development program for Tecentriq in bladder cancer, as well as their methodology of merging immunotherapy with chemotherapy or other medicines to improve patient outcomes.

Reportedly, Tecentriq was the first cancer immunology approved in bladder cancer and has gained approval from the FDA for the treatment of adults with mUC or locally advanced, counting those who are not fit for cisplatin-containing chemotherapy and whose tumors express high levels of PD-L1 as determined by an FDA-approved test or are not eligible for any platinum-containing chemotherapy irrespective of PD-L1 status.

Additionally, the accelerated approval contains the treatment of adults with locally advanced or mUC whose disease had developed during or following platinum-containing chemotherapy, or within a year of receiving chemotherapy before or after surgery.

These accelerated approvals are also based on durability of response and tumor response rate. Meanwhile, continued approvals in these sorts of bladder cancer may be depended upon verification and description of clinical benefit in a confirmatory trial, claim sources.

As per reports, there are currently four Phase III studies assessing Tecentriq alone and in combination with other medications in early and advanced bladder cancer. Whereas Genentech has a wide-ranging development program for Tecentriq, including multiple ongoing and planned Phase III studies, across genitourinary, lung, breast, skin, gynecological, gastrointestinal and head and neck cancers.

Source Credit: https://www.gene.com/media/press-releases/14801/2019-08-04/genentechs-tecentriq-atezolizumab-plus-p

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Delta and Virgin Atlantic to expand transatlantic services by 2020
Delta and Virgin Atlantic to expand transatlantic services by 2020
By Mateen Dalal

This will be the first time that both the carriers will be serving Gatwick airport since their partnership in 2014 British airlines Virgin Atlantic and the American airline Delta recently announced increased services between the US and UK by the yea...

Ola acquires AI firm Pikup.ai to further enhance its deep tech skills
Ola acquires AI firm Pikup.ai to further enhance its deep tech skills
By Mateen Dalal

Startup Pikup.ai utilizes automated technologies like sensor fusion, computer vision, and Artificial Intelligence to offer AI-based solutions for businesses.   Ola is increasing company’s aim on utilizing deep technology and advanced a...

Sonnet to acquire Relief Therapeutics to develop atexakin alfa
Sonnet to acquire Relief Therapeutics to develop atexakin alfa
By Mateen Dalal

Sonnet proposes to pay 7,111,947 common shares and outstanding common stocks to Relief Therapeutics. Sonnet BioTherapeutics, Inc., a biotechnology company that develops innovative biologic drugs, has recently announced that it has entered into an ag...